Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 65.65 Thousand USD | -87.65% |
| 2021 | 531.51 Thousand USD | -41.91% |
| 2020 | 915.01 Thousand USD | 3337.57% |
| 2019 | 26.61 Thousand USD | -91.75% |
| 2018 | 322.52 Thousand USD | -82.19% |
| 2017 | 1.81 Million USD | -91.76% |
| 2016 | 21.96 Million USD | 65.82% |
| 2015 | 13.24 Million USD | 111.15% |
| 2014 | 6.27 Million USD | 454.99% |
| 2013 | 1.13 Million USD | 1335.94% |
| 2012 | 78.73 Thousand USD | -86.83% |
| 2011 | 597.72 Thousand USD | -94.41% |
| 2010 | 10.7 Million USD | 12.42% |
| 2009 | 9.51 Million USD | 20.69% |
| 2008 | 7.88 Million USD | 10.69% |
| 2007 | 7.12 Million USD | 17.74% |
| 2006 | 6.05 Million USD | 2.22% |
| 2005 | 5.91 Million USD | -0.56% |
| 2004 | 5.95 Million USD | -8.56% |
| 2003 | 6.5 Million USD | 32.29% |
| 2002 | 4.92 Million USD | -35.11% |
| 2001 | 7.58 Million USD | -21.9% |
| 2000 | 9.71 Million USD | 2.8% |
| 1999 | 9.44 Million USD | 61.94% |
| 1998 | 5.83 Million USD | 13.74% |
| 1997 | 5.12 Million USD | 337.84% |
| 1996 | 1.17 Million USD | 17.12% |
| 1995 | 1 Million USD | 11.11% |
| 1994 | 900 Thousand USD | 800.0% |
| 1993 | 100 Thousand USD | 0.0% |
| 1992 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q3 | 7516.00 USD | 15.29% |
| 2022 Q4 | 610.00 USD | -91.88% |
| 2022 FY | 65.65 Thousand USD | -87.65% |
| 2022 Q1 | - USD | -100.0% |
| 2022 Q2 | 6519.00 USD | 0.0% |
| 2021 Q3 | 96.38 Thousand USD | -63.08% |
| 2021 Q4 | 50.34 Thousand USD | -47.76% |
| 2021 Q2 | 261.04 Thousand USD | 110.97% |
| 2021 FY | 531.51 Thousand USD | -41.91% |
| 2021 Q1 | 123.73 Thousand USD | -43.56% |
| 2020 Q4 | 219.25 Thousand USD | 3137.13% |
| 2020 FY | 915.01 Thousand USD | 3337.57% |
| 2020 Q1 | 15.22 Thousand USD | 467.95% |
| 2020 Q2 | 8920.00 USD | -41.4% |
| 2020 Q3 | 6773.00 USD | -24.07% |
| 2019 Q1 | 97.55 Thousand USD | 178.42% |
| 2019 FY | 26.61 Thousand USD | -91.75% |
| 2019 Q4 | 2680.00 USD | -45.25% |
| 2019 Q3 | 4895.00 USD | -69.2% |
| 2019 Q2 | 15.89 Thousand USD | -83.71% |
| 2018 FY | 322.52 Thousand USD | -82.19% |
| 2018 Q4 | 35.04 Thousand USD | 57.05% |
| 2018 Q3 | 22.31 Thousand USD | -91.56% |
| 2018 Q2 | 264.37 Thousand USD | 33154.59% |
| 2018 Q1 | 795.00 USD | -99.8% |
| 2017 Q3 | 223.66 Thousand USD | -63.43% |
| 2017 Q4 | 395.13 Thousand USD | 76.66% |
| 2017 Q2 | 611.59 Thousand USD | 5.44% |
| 2017 FY | 1.81 Million USD | -91.76% |
| 2017 Q1 | 580.03 Thousand USD | -82.71% |
| 2016 Q2 | 5.39 Million USD | 14.23% |
| 2016 FY | 21.96 Million USD | 65.82% |
| 2016 Q4 | 3.35 Million USD | -60.51% |
| 2016 Q3 | 8.49 Million USD | 57.51% |
| 2016 Q1 | 4.72 Million USD | 9.99% |
| 2015 FY | 13.24 Million USD | 111.15% |
| 2015 Q4 | 4.29 Million USD | 7.9% |
| 2015 Q2 | 2.86 Million USD | 36.02% |
| 2015 Q3 | 3.97 Million USD | 38.75% |
| 2015 Q1 | 2.1 Million USD | -4.09% |
| 2014 Q3 | 2.25 Million USD | 109.37% |
| 2014 Q2 | 1.07 Million USD | 42.95% |
| 2014 FY | 6.27 Million USD | 454.99% |
| 2014 Q1 | 751.8 Thousand USD | 40.53% |
| 2014 Q4 | 2.19 Million USD | -2.3% |
| 2013 FY | 1.13 Million USD | 1335.94% |
| 2013 Q4 | 534.97 Thousand USD | 33.62% |
| 2013 Q2 | 195.27 Thousand USD | 0.0% |
| 2013 Q3 | 400.37 Thousand USD | 105.03% |
| 2013 Q1 | - USD | -100.0% |
| 2012 FY | 78.73 Thousand USD | -86.83% |
| 2012 Q4 | 6807.00 USD | -97.99% |
| 2012 Q3 | 339 Thousand USD | 465.0% |
| 2012 Q2 | 60 Thousand USD | 402.89% |
| 2012 Q1 | 11.93 Thousand USD | 100.19% |
| 2011 Q2 | 3.19 Million USD | 12.56% |
| 2011 FY | 597.72 Thousand USD | -94.41% |
| 2011 Q4 | -6.29 Million USD | -2560.84% |
| 2011 Q3 | 255.63 Thousand USD | -92.0% |
| 2011 Q1 | 2.83 Million USD | -10.58% |
| 2010 Q2 | 2.53 Million USD | -5.37% |
| 2010 Q3 | 2.3 Million USD | -9.27% |
| 2010 Q4 | 3.17 Million USD | 37.84% |
| 2010 FY | 10.7 Million USD | 12.42% |
| 2010 Q1 | 2.68 Million USD | 9.74% |
| 2009 FY | 9.51 Million USD | 20.69% |
| 2009 Q4 | 2.44 Million USD | -5.5% |
| 2009 Q2 | 1.83 Million USD | -32.71% |
| 2009 Q3 | 2.58 Million USD | 41.08% |
| 2009 Q1 | 2.72 Million USD | 33.05% |
| 2008 Q3 | 1.8 Million USD | -20.17% |
| 2008 Q2 | 2.25 Million USD | 26.49% |
| 2008 Q1 | 1.78 Million USD | -5.12% |
| 2008 Q4 | 2.04 Million USD | 13.77% |
| 2008 FY | 7.88 Million USD | 10.69% |
| 2007 FY | 7.12 Million USD | 17.74% |
| 2007 Q4 | 1.87 Million USD | -5.34% |
| 2007 Q3 | 1.98 Million USD | 30.82% |
| 2007 Q2 | 1.51 Million USD | -12.96% |
| 2007 Q1 | 1.74 Million USD | -6.83% |
| 2006 Q1 | 1.78 Million USD | 25.98% |
| 2006 FY | 6.05 Million USD | 2.22% |
| 2006 Q3 | 957.95 Thousand USD | -33.2% |
| 2006 Q2 | 1.43 Million USD | -19.8% |
| 2006 Q4 | 1.87 Million USD | 95.33% |
| 2005 FY | 5.91 Million USD | -0.56% |
| 2005 Q2 | 1.7 Million USD | 16.03% |
| 2005 Q4 | 1.41 Million USD | 6.42% |
| 2005 Q3 | 1.33 Million USD | -21.6% |
| 2005 Q1 | 1.46 Million USD | 16.9% |
| 2004 Q1 | 1.42 Million USD | -24.79% |
| 2004 Q2 | 1.54 Million USD | 8.58% |
| 2004 Q3 | 1.72 Million USD | 11.45% |
| 2004 Q4 | 1.25 Million USD | -27.31% |
| 2004 FY | 5.95 Million USD | -8.56% |
| 2003 Q1 | 1.53 Million USD | -8.14% |
| 2003 FY | 6.5 Million USD | 32.29% |
| 2003 Q4 | 1.89 Million USD | 59.9% |
| 2003 Q3 | 1.18 Million USD | -37.26% |
| 2003 Q2 | 1.88 Million USD | 22.79% |
| 2002 Q2 | 1.26 Million USD | 19.34% |
| 2002 Q1 | 1.06 Million USD | -44.04% |
| 2002 FY | 4.92 Million USD | -35.11% |
| 2002 Q4 | 1.67 Million USD | 82.17% |
| 2002 Q3 | 919.76 Thousand USD | -27.31% |
| 2001 Q3 | 1.79 Million USD | -21.3% |
| 2001 FY | 7.58 Million USD | -21.9% |
| 2001 Q2 | 2.27 Million USD | 40.63% |
| 2001 Q1 | 1.61 Million USD | -42.53% |
| 2001 Q4 | 1.89 Million USD | 5.71% |
| 2000 Q4 | 2.81 Million USD | 21.19% |
| 2000 Q2 | 2.71 Million USD | 46.12% |
| 2000 Q1 | 1.85 Million USD | -56.02% |
| 2000 FY | 9.71 Million USD | 2.8% |
| 2000 Q3 | 2.32 Million USD | -14.26% |
| 1999 Q3 | 1.4 Million USD | -26.32% |
| 1999 Q2 | 1.9 Million USD | 0.0% |
| 1999 Q4 | 4.22 Million USD | 201.43% |
| 1999 Q1 | 1.9 Million USD | -6.53% |
| 1999 FY | 9.44 Million USD | 61.94% |
| 1998 Q4 | 2.03 Million USD | 19.57% |
| 1998 Q1 | 900 Thousand USD | -44.71% |
| 1998 FY | 5.83 Million USD | 13.74% |
| 1998 Q2 | 1.3 Million USD | 44.44% |
| 1998 Q3 | 1.7 Million USD | 30.77% |
| 1997 Q2 | 1.1 Million USD | 0.0% |
| 1997 Q4 | 1.62 Million USD | 25.22% |
| 1997 Q3 | 1.3 Million USD | 18.18% |
| 1997 FY | 5.12 Million USD | 337.84% |
| 1997 Q1 | 1.1 Million USD | 92.58% |
| 1996 FY | 1.17 Million USD | 17.12% |
| 1996 Q4 | 571.18 Thousand USD | 185.59% |
| 1996 Q3 | 200 Thousand USD | 0.0% |
| 1996 Q2 | 200 Thousand USD | 0.0% |
| 1996 Q1 | 200 Thousand USD | -33.33% |
| 1995 Q3 | 100 Thousand USD | -66.67% |
| 1995 Q4 | 300 Thousand USD | 200.0% |
| 1995 FY | 1 Million USD | 11.11% |
| 1995 Q2 | 300 Thousand USD | 0.0% |
| 1995 Q1 | 300 Thousand USD | -25.0% |
| 1994 FY | 900 Thousand USD | 800.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 200 Thousand USD | 100.0% |
| 1994 Q3 | 200 Thousand USD | 0.0% |
| 1994 Q4 | 400 Thousand USD | 100.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1992 FY | 100 Thousand USD | 0.0% |
| 1992 Q3 | 100 Thousand USD | 0.0% |
| 1992 Q4 | - USD | -100.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | 67.499% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 4.52 Million USD | 98.55% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | 18.948% |
| Azitra, Inc. | 686 Thousand USD | 90.43% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 91.164% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| iBio, Inc. | 225 Thousand USD | 70.821% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 99.266% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | 94.01% |
| NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 99.554% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 37.65 Thousand USD | -74.361% |
| BiomX Inc. | -357 Thousand USD | 118.39% |
| BiomX Inc. | -357 Thousand USD | 118.39% |
| Protalix BioTherapeutics, Inc. | 65.49 Million USD | 99.9% |
| Palatin Technologies, Inc. | 4.49 Million USD | 98.538% |
| Scorpius Holdings, Inc. | 6.99 Million USD | 99.061% |